Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers [0.03%]
polo样激酶1在非小细胞肺癌中的抑制：作用机制和预测生物标志物的出现
Jan A Stratmann,Martin Sebastian
Jan A Stratmann
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Due to often unspecific disease symptoms, locally advanced or metastatic disease is diagnosed in the majority of all cases. Palliative treatment options comp...
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer [0.03%]
派姆单抗联合化疗成为晚期非小细胞肺癌患者的新标准治疗方案
Frank Weinberg,Shirish Gadgeel
Frank Weinberg
Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The...
Pain management in patients with malignant mesothelioma: challenges and solutions [0.03%]
恶性间皮瘤患者的疼痛管理：挑战与对策
J Saunders,M Ashton,C Hall et al.
J Saunders et al.
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a considerable symptom burden and poor prognosis. Focus on maintaining patients' quality of life and pain control is therefore paramount. Pain management in MPM is complex du...
Giuseppe Bronte,Paola Ulivi,Alberto Verlicchi et al.
Giuseppe Bronte et al.
Non-small-cell lung cancer (NSCLC) patients with mutated or rearranged oncogene drivers can be treated with upfront selective inhibitors achieving higher response rates and longer survival than chemotherapy. The RET gene can undergo chromos...
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification [0.03%]
EGFR突变非小细胞肺癌伴MET扩增患者接受奥希替尼和克唑替尼全剂量联合治疗的疗效分析
Viola W Zhu,Alexa B Schrock,Siraj M Ali et al.
Viola W Zhu et al.
Exploring resistance mechanisms in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an area of great interest as it may lead to effective next-line trea...
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer [0.03%]
ALK阳性非小细胞肺癌序贯使用ALK抑制剂的系统评价
Stephanie M Barrows,Kelly Wright,Catherine Copley-Merriman et al.
Stephanie M Barrows et al.
The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochran...
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis [0.03%]
罕见EGFR突变阳性晚期非小细胞肺癌一线治疗疗效分析：单中心回顾性研究
Shruti Kate,Anuradha Chougule,Amit Joshi et al.
Shruti Kate et al.
Background: The significance of uncommon EGFR mutations in newly diagnosed advanced non-small-cell lung cancer (NSCLC) patients is incompletely known. We aimed to analyze the demographic profile, outcome, and treatment at...
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation [0.03%]
一种新型VKORC1L1-ALK融合和获得性ALK T1151K突变的肺癌患者对阿来替尼有戏剧性的反应
Viola W Zhu,Alexa B Schrock,Thangavijayan Bosemani et al.
Viola W Zhu et al.
ALK-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this dri...
Takashi Sato,Takeshi Shimosato,Dennis M Klinman
Takashi Sato
"Silica" refers to crystalline particles formed by the combination of silicon with oxygen. Inhalation of silica particles promotes the development of pulmonary fibrosis that over prolonged periods increases the risk of lung cancer. The Inte...
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation [0.03%]
PD-1抑制剂治疗过程中非小细胞肺癌向小细胞肺癌的转化：两例报告及文献复习
Nadine Abdallah,Misako Nagasaka,Eman Abdulfatah et al.
Nadine Abdallah et al.
Introduction: Histologic transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is a well-recognized mechanism of resistance in EGFR-mutant adenocarcinoma upon treatment with TKIs, but rar...